Therapy News and Research

RSS

FDA grants compassionate case for use of novel wet age-related macular degeneration treatment

NeoVista, Inc., announced today that the U.S. Food and Drug Administration (FDA) had approved the company's "compassionate case" waiver to utilize its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of the disease who did not meet criteria for inclusion into current NeoVista investigational treatment protocols.

10 Dec 2008

Blocking immune receptor molecule improves response to HIV-like virus, prolongs survival in monkeys

By blocking PD-1 (programmed death-1), an immune receptor molecule known to inhibit the immune response to chronic viral infections, scientists have safely and significantly reduced the plasma viral load and also prolonged survival of rhesus macaque monkeys severely infected with simian immunodeficiency virus (SIV), the nonhuman primate version of human immunodeficiency virus (HIV).

10 Dec 2008

New class of anti-inflammatory drugs

In the treatment of pain, inflammation and fever, non-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid - more commonly known as Aspirin - or Ibuprofen have always been popular choices.

10 Dec 2008

$Thiazolidinediones doubles risk of fractures in women$

Thiazolidinediones doubles risk of fractures in women

New findings out of Wake Forest University School of Medicine and the University of East Anglia show that long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes.

10 Dec 2008

UK kidney cancer patients face toxic, out-dated treatments with little hope of change

Leading oncologist Professor Tim Eisen has expressed concerns that patients with advanced kidney cancer could be condemned to toxic, barely effective, 20 year-old treatments because the National Institute for Health and Clinical Excellence (NICE) is likely to rule out using all four of the new treatments it has assessed.

10 Dec 2008

UK's first prostate cancer patient treated using RapidArc radiotherapy

65-year-old grandfather of six, Graham McCormack has become the first cancer patient in the UK to be treated using RapidArc radiotherapy technology from Varian Medical Systems.

10 Dec 2008

Experimental drug successfully blocks mutation in bone marrow cancers

Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.

10 Dec 2008

Advances in tissue engineering

Some patients wish they had a second skin - for instance because their own skin has been burnt in a severe accident.

10 Dec 2008

Potential breakthrough for T-cell lymphoma

Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).

10 Dec 2008

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals has announced that it has initiated patient enrollment in INNOVATE-PCI, a large Phase II clinical trial of PRT060128, the Company's novel P2Y12 ADP receptor antagonist, in patients undergoing non-urgent percutaneous coronary intervention (PCI).

10 Dec 2008

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.

10 Dec 2008

Merck Serono's Kuvan receives European marketing authorization

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for Kuvan(R) for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients.

10 Dec 2008

Amblyopia treatment times could be drastically reduced

Amblyopia is thought to affect up to 2.5 per cent of people and accounts for around 90 per cent of all children's eye appointments in the UK. Occlusion therapy - patching the normal eye for lengthy periods to 'train' the affected eye - is the main treatment for amblyopia.

10 Dec 2008

Intense chemo wards off recurrence in half of mantle cell lymphoma patients after seven years

More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

10 Dec 2008

Hep C treatment pegylated interferon reduces the virus but liver damage continues

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.

10 Dec 2008

New discovery on cell division could improve chemotherapies for cancer

Researchers from the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine have identified a key step required for cell division in a study that could help improve therapies to treat cancer.

10 Dec 2008

$EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients$

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.

10 Dec 2008

Researchers hunt for a hi-tech vaccine against Helicobacter pylori

Almost half of the world population is infected with bacteria Helicobacter pylori which colonizes stomach, causing gastritis and ulcers and is recognized by WHO as a type I carcinogen.

10 Dec 2008

Drug combo improves or stabilizes disease for relapsed multiple myeloma patients

Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment.

10 Dec 2008

Doctors question FDA suicide alert on anticonvulsant drugs

Medical specialists at the nation's largest professional meeting on epilepsy discussed multiple questions and concerns they have about data presented by the FDA in support of its recent suicide alert on anticonvulsant drugs (AEDs) and the potential effect of the federal agency's analyses on clinical practice and the way AED drug trials are to be conducted in the future.

10 Dec 2008

Therapy News and Research

FDA grants compassionate case for use of novel wet age-related macular degeneration treatment

Blocking immune receptor molecule improves response to HIV-like virus, prolongs survival in monkeys

New class of anti-inflammatory drugs

Thiazolidinediones doubles risk of fractures in women

UK kidney cancer patients face toxic, out-dated treatments with little hope of change

UK's first prostate cancer patient treated using RapidArc radiotherapy

Experimental drug successfully blocks mutation in bone marrow cancers

Advances in tissue engineering

Potential breakthrough for T-cell lymphoma

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Merck Serono's Kuvan receives European marketing authorization

Amblyopia treatment times could be drastically reduced

Intense chemo wards off recurrence in half of mantle cell lymphoma patients after seven years

Hep C treatment pegylated interferon reduces the virus but liver damage continues

New discovery on cell division could improve chemotherapies for cancer

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

Researchers hunt for a hi-tech vaccine against Helicobacter pylori

Drug combo improves or stabilizes disease for relapsed multiple myeloma patients

Doctors question FDA suicide alert on anticonvulsant drugs

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News